How often is the planned dose intensity of XELOX and FOLFOX administered to colon cancer patients older than age 65 in clinical practice?

Abstract

e14113 Background: The addition of oxaliplatin to FU/LV has been shown to significantly prolong DFS in patients (pts) with stage II/III colon cancer. Capecitabine can replace bolus FU/LV, with the added benefit of the convenient oral administration compared with more-cumbersome infusional therapy. XELOX regimen was compared to bolus FU/LV in 1,886 resected colorectal cancer pts, showing superior DFS, but higher rate of withdrawals for toxicity, especially in over 65 years pts (30% vs. 9%). Given this threefold rate of toxicity-related interruptions reported for XELOX, we performed a retrospective analysis to verify if the dose intensity of chemotherapy is administered in routine clinical practice in a consecutive non-selected series of over 65 years pts with resected colorectal cancer. Methods: All pts over 65 years, treated with adjuvant FOLFOX or XELOX, between 01/08-12/10, were retrospectively identified. We assessed the completion of the prescribed adjuvant chemotherapy and dose reduction due to toxic...